Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy

AIDS

Volumn 17, Issue 7, 2003, Pages 971-979

  Mallon, Patrick W G ^a,b   Miller, John ^b   Cooper, David A ^a   Carr, Andrew ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Adipose tissue; Densitometry; Highly active antiretroviral therapy; HIV; Lipodystrophy; Metabolic syndrome X; X ray

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BONE DENSITY; CLINICAL ARTICLE; DRUG EFFECT; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; LEAN BODY WEIGHT; LIPODYSTROPHY; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME; VIRUS LOAD; WEIGHT GAIN;

ADIPOSE TISSUE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; BONE DENSITY; CHOLESTEROL, LDL; COHORT STUDIES; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; PROSPECTIVE STUDIES;

EID: 0038708272     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200305020-00005     Document Type: Article

References (23)

1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-58.
2. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with the use of indinavir. Lancet 1998, 351:871-875.
3. Shikuma CM, Hu N, Milne C, Yost F, Waslien C, Shimizu S, et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV infected individuals with peripheral lipoatrophy. AIDS 2001, 15:1801-1809.
4. Brinkman K, Smeitink JA, Romijn HA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-related lipodystrophy. Lancet 1999, 354:1112-1115.
5. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localisation, inhibits pre-adipocyte differentiation, and induces insulin resistance. Diabetes 2001, 50:1378-1388.
6. Dowell P, Flexner C, Kwiterovich P, Lane MD. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem 2000, 275:41325-41332.
7. Domingo P, Matias-Guiu X, Pujol R P, Francia E, Lagarda E, Sambeat M A, et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 1999, 13:2261-2267.
8. Ledru E, Christeff N, Patey O, de Truchis P, Melchior J-C, Gougeon M-L. Alteration of tumor necrosis factor-(T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 2000, 95:3191-3198.
9. van der Valk M, Gisolf EH, Wit FWNM, Japour A, Weverling GJ, Danner SA on behalf of the Promethus study group. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001, 15:847-855.
10. Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001, 357:592-598.
11. Thiebaut R, Daucourt V, Mercie P, Ekouevi DK, Malvy D, Morlat P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Clin Infect Dis 2000, 31:1482-1487.
12. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ Jr, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001, 15:1389-1398.
13. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000, 14:F25-F32.
14. Boufassa F, Dulioust A, Lascaux AS, Meyer L, Boue F, Delfraissy JF, et al. Lipodytrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response. HIV Clin Trials 2001, 2:339-345.
15. Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus. Lancet 1999, 353:2893-2899.
16. Mynarcik D C, McNurlan M A, Steigbigel R T, Fuhrer J, Gelaot MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000, 25:312-321.
17. Bogner JR, Vielhauer V, Beckmann RA, Michl G, Wille L, Salzberger B, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr 2001, 27:237-244.
18. Miserez AR, Muller PY, Barella L, Schwietert M, Erb P, Vernazza PL, et al. A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia. AIDS 2001, 15:2045-2049.
19. Gan S K, Samaras K, Thompson C, Kraegen E, Carr A, Cooper D, et al. Correlations between intramyocellular lipid, visceral fat and insulin sensitivity: a study of HIV positive subjects with and without peripheral lipodystrophy. Diabetes 2002, 51:3163-3169.
20. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women. Diabetes 1996, 45:633-638.
21. Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, et al. Metabolic effects of indinavir in healthy HIV-seronegative subjects. AIDS 2001, 15:F11-F18
22. Murata H, Hruz P W, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000, 275:20251-20254.
23. Dube MP, Qian D, Edmondson-Melancon H, Sattler FR, Goodwin D, Martinez C, et al. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 2002, 35:475-481.